Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Total Liabilities (2016 - 2025)

Apyx Medical's Total Liabilities history spans 16 years, with the latest figure at $52.0 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 2.97% year-over-year to $52.0 million; the TTM value through Dec 2025 reached $52.0 million, up 2.97%, while the annual FY2025 figure was $52.0 million, 2.97% up from the prior year.
  • Total Liabilities reached $52.0 million in Q4 2025 per APYX's latest filing, up from $51.3 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $52.3 million in Q4 2023 to a low of $10.9 million in Q1 2021.
  • Average Total Liabilities over 5 years is $31.6 million, with a median of $25.8 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: fell 6.49% in 2021, then soared 274.18% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $14.7 million in 2021, then fell by 4.96% to $14.0 million in 2022, then skyrocketed by 274.18% to $52.3 million in 2023, then dropped by 3.46% to $50.5 million in 2024, then grew by 2.97% to $52.0 million in 2025.
  • Per Business Quant, the three most recent readings for APYX's Total Liabilities are $52.0 million (Q4 2025), $51.3 million (Q3 2025), and $50.7 million (Q2 2025).